|
Entry |
Name |
Definition |
|
N00081
|
Mutation-inactivated VHL to HIF-1 signaling pathway
|
(VHL*+RBX1+ELOC+ELOB+CUL2) ⌿ HIF1A == ARNT ⇒ (SLC2A1,VEGFA,TGFB,PDGFB,TGFA)
|
|
N00082
|
Loss of NKX3-1 to PI3K signaling pathway
|
NKX3-1* ⌿ AKT ⊣ BAD
|
|
N00083
|
Androgen receptor signaling pathway
|
(T,DHT) → AR ⇒ KLK3
|
|
N00084
|
Amplified AR to androgen receptor signaling pathway
|
(T,DHT) → AR* ⇒ KLK3
|
|
N00085
|
Mutation-activated AR to androgen receptor signaling pathway
|
(T,DHT,E2,P4,FLUT,DHA,A4,F,E) → AR* ⇒ KLK3
|
|
N00086
|
Notch signaling pathway
|
(DLL,JAG) → NOTCH → (NICD+RBPJ) ⇒ (HES1,HEY1)
|
|
N00087
|
NOTCH-overexpression to Notch signaling pathway
|
(DLL,JAG) → (NOTCH1*,NOTCH4*) → (NICD+RBPJ) ⇒ (ERBB2,HES1,HES5,HEY,FLT4)
|
|
N00088
|
Amplified MYC to p15-cell cycle G1/S
|
(MYC*+MAX) ⊣ ZBTB17 ⇒ CDKN2B ⊣ (CCND+CDK4/6) → RB1 ⌿ E2F
|
|
N00089
|
Amplified MYC to cell cycle G1/S
|
(MYC*+MAX) ⇒ (CCND+CDK4/6) → RB1 ⌿ E2F
|
|
N00090
|
p15-Cell cycle G1/S
|
(MYC+MAX) ⊣ ZBTB17 ⇒ CDKN2B ⊣ (CCND+CDK4/6) → RB1 ⌿ E2F
|
|
N00091
|
p27-Cell cycle G1/S
|
(SCF+SKP2) ⊣ CDKN1B ⊣ ((CCNA,CCNE)+CDK2) → RB1 ⌿ E2F
|
|
N00092
|
Amplified MYC to p27-cell cycle G1/S
|
(MYC*+MAX) ⇒ CKS1B → (SCF+SKP2) ⊣ CDKN1B ⊣ (CCNE+CDK2) → RB1 ⌿ E2F
|
|
N00093
|
Loss of CDKN1B to p27-cell cycle G1/S
|
CDKN1B* ⌿ (CCNE+CDK2) → RB1 ⌿ E2F
|
|
N00094
|
EGF-Jak-STAT signaling pathway
|
EGF → EGFR → JAK1 → STAT1/3/5
|
|
N00095
|
ERBB2-overexpression to EGF-Jak-STAT signaling pathway
|
EGF → (ERBB2*+EGFR) → JAK1 → STAT1/3 ⇒ VEGFA
|
|
N00096
|
EGF-EGFR-RAS-RASSF1 signaling pathway
|
EGF → EGFR → GRB2 → SOS → RAS → (RASSF1+RASSF5) → STK4
|
|
N00097
|
Loss of RASSF1 to RAS-RASSF1 signaling pathway
|
RAS ⌿ (RASSF1*+RASSF5) ⌿ STK4
|
|
N00098
|
Intrinsic apoptotic pathway
|
(PMAIP1,BBC3,BAD,BCL2L11) ⊣ (BCL2,BCL2L1) ⊣ (BAX,BAK1) → CYCS == APAF1 → CASP9 → (CASP3,CASP7)
|
|
N00099
|
Mutation-inactivated BAX to apoptotic pathway
|
BAX* ⌿ CYCS
|
|
N00100
|
BCL2-overexpression to intrinsic apoptotic pathway
|
BCL2* ⊣ BAX → CYCS == APAF1 → CASP9 → (CASP3,CASP7)
|
|
N00101
|
DCC-apoptotic pathway
|
CASP3 → DCC → (CASP9+APPL1) → CASP3
|
|
N00102
|
Loss of DCC to DCC-apoptotic pathway
|
CASP3 ⌿ DCC* ⌿ (CASP9+APPL1)
|
|
N00103
|
EGF-EGFR-RAS-RalGDS signaling pathway
|
EGF → EGFR → GRB2 → SOS → RAS → RALGDS → RAL
|
|
N00104
|
Mutation-activated KRAS to RalGDS signaling pathway
|
KRAS* → RALGDS → RAL
|
|
N00105
|
EML4-ALK fusion kinase to Jak-STAT signaling pathway
|
EML4-ALK → JAK3 → STAT3,STAT5
|
|
N00106
|
AML1-EVI1 fusion to TGF-beta signaling pathway
|
AML1-EVI1 ⊣ SMAD3 == SMAD4
|
|
N00107
|
EVI-1 overexpression to TGF-beta signaling pathway
|
EVI1* ⊣ SMAD3 == SMAD4
|
|
N00108
|
AML1-ETO fusion to transcriptional activtion
|
AML1-ETO ⇒ JUP
|
|
N00109
|
PML-RARA fusion to transcriptional activtion
|
PML-RARA ⇒ (JUP,CCNA1)
|
|
N00110
|
PLZF-RARA fusion to transcriptional activtion
|
PLZF-RARA ⇒ (JUP,CCNA1,MYC)
|
|
N00111
|
AML1-ETO fusion to CEBPA-mediated transcription
|
AML1-ETO ⊣ CEBPA ⇒ PER2
|
|
N00112
|
AML1-ETO fusion to PU.1-mediated transcription
|
AML1-ETO ⊣ SPI1 ⇒ (CD14,ITGAM,FCGR1A)
|
|
N00113
|
PML-RARA fusion to transcriptional repression
|
PML-RARA ⫤ (CEBPE,BCL2A1)
|
|
N00114
|
PLZF-RARA fusion to transcriptional repression
|
PLZF-RARA ⫤ DUSP6
|
|
N00115
|
Mutation-inactivated TP53 to transcription
|
TP53* ⌿ (CDKN1A,GADD45,BAX,BAK1,DDB2,POLK)
|
|
N00116
|
Mutation-inactivated RUNX1 to transcription
|
RUNX1* ⌿ (CSF1R,MPO,CSF2,IL3)
|
|
N00117
|
E2A-PBX1 fusion to transcriptional activation
|
E2A-PBX1 ⇒ WNT16
|
|
N00118
|
TEL-AML1 fusion to transcriptional repression
|
TEL-AML1 == (HDAC+SIN3A+NCOR1) ⫤ (IL3,CSF2,MPO,DEFA3,ELANE,GZMB)
|
|
N00119
|
MLL-AF4 fusion to transcriptional activation
|
MLL-AF4 == ((CDK9,CCNT)+(MLLT1,MLLT3)+DOT1L) ⇒ (LMO2,PBX3,RUNX2,SMAD1,KLF3,MEF2C,HOXA9,HOXA10,JMJD1C,HMGA2,KDM6A,SUPT3H,PROM1,FLT3,BMP2K,IGF1R,CDKN1B,CDK14)
|
|
N00120
|
MLL-ENL fusion to transcriptional activation
|
MLL-ENL ⇒ (MEIS1,HOXA9,HOXA10,HOXA11,SIX1,SIX4,EYA1,CDKN2C,HPGD,GRIA3,FUT8)
|